RALEIGH — Aniluxx Biotechnology, a development stage biopharmaceutical company with a mission to improve animal health and well-being, has raised $200,000 in debt and option.
Two investors contributed to the round, according to the recent SEC filing.
The round is capped at $750,000 with $550,000 remaining to be sold.
The filing indicated that the startup would use proceeds for working capital, which may include normal compensation to executive officers.
Aniluxx develops novel topical therapeutics for animals suffering from skin diseases. According to its website, the formulas are “easy to apply, virtually unnoticeable, and do not have the harsh side effects of oral medicines.”
In October, the company received $100,000 from the North Carolina Biotechnology Center for a clinical proof-of-concept study of topical foam formulations to treat atopic dermatitis in dogs.
